(0)
Fund launched in July 2020 invests in late-stage European life science companies
Fund now closed at the hard cap, with investors that include Pantheon, Eli Lilly and Company, Horizon Therapeutics plc (Nasdaq: HZNP), the Belgian Growth Fund, New Waves Investments, Wealth Management Partners, KfW Capital and the European Investment Fund (EIF)
First three investments made from fund
Forbion, a leading European life sciences venture capital firm, today announces the final close of its Forbion Growth Opportunities Fund I ( Forbion Growth I ) at the hard cap amount of EUR 360 million (USD 428 million). Forbion Growth I is focused on investing in late-stage European life sciences companies.
Forbion Announces Final Close of Forbion Growth Opportunities Fund I at EUR 360 Million (USD 428 Million) financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.